Gynecologic Cancers

Encourage Minority Patients with Ovarian Cancer to Participate in Clinical Trials

Meg Barbor, MPH

June 2018, Vol 8, No 6 - Gynecologic Cancers

Participation in clinical trials may help to overcome health disparities in the treatment of advanced or recurrent ovarian cancer, and minority patients should be encouraged to participate, said Khilen B. Patel, MD, Obstetrics & Gynecology Resident, Medical College of Georgia, Augusta University, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. [ Read More ]

Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy

Charles Bankhead

July 2017, Vol 7, No 7 - Gynecologic Cancers

National Harbor, MD—Pa­tients with relapsed high-grade ovarian cancer with BRCA mutation derived the greatest benefit from the poly ADP-­ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting. [ Read More ]